Aristides Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Aristides Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4,800	Closed	-$535K	–	182
2020 Q3	$535K	Buy	+4,800	New	+$538K	0.37%	50
2020 Q2	–	Sell	-15,000	Closed	-$1.16M	–	177
2020 Q1	$1.16M	Buy	+15,000	New	+$1.33M	0.84%	24

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return

Aristides Capital's XBI Position: Q4 2020 in Review

Aristides Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2020, closing a stake of 4,800 shares — an estimated $535K sold.

Aristides Capital first reported a position in XBI in Q1 2020 and held it in 2 quarters. The position peaked at $1.16M in Q1 2020. 654 funds tracked by Wall St. Rank hold XBI as of Q4 2020.

Aristides Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2020 after selling out during the quarter.
Aristides Capital sold 4,800 State Street SPDR S&P Biotech ETF shares in Q4 2020, an estimated $535K.
Aristides Capital first reported a position in State Street SPDR S&P Biotech ETF in Q1 2020 and held it in 2 quarters.
Aristides Capital's State Street SPDR S&P Biotech ETF position peaked at $1.16M in Q1 2020.
654 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2020.

Based on Aristides Capital's 13F filing for Q4 2020, filed 12 Feb 2021.